| Literature DB >> 19717648 |
Rekha Pal1, Martin Janz, Deborah L Galson, Margarete Gries, Shirong Li, Korinna Jöhrens, Ioannis Anagnostopoulos, Bernd Dörken, Markus Y Mapara, Lisa Borghesi, Lela Kardava, G David Roodman, Christine Milcarek, Suzanne Lentzsch.
Abstract
CCAAT/enhancer-binding protein beta (C/EBPbeta), also known as nuclear factor-interleukin-6 (NF-IL6), is a transcription factor that plays an important role in the regulation of growth and differentiation of myeloid and lymphoid cells. Mice deficient in C/EBPbeta show impaired generation of B lymphocytes. We show that C/EBPbeta regulates transcription factors critical for proliferation and survival in multiple myeloma. Multiple myeloma cell lines and primary multiple myeloma cells strongly expressed C/EBPbeta, whereas normal B cells and plasma cells had little or no detectable levels of C/EBPbeta. Silencing of C/EBPbeta led to down-regulation of transcription factors such as IRF4, XBP1, and BLIMP1 accompanied by a strong inhibition of proliferation. Further, silencing of C/EBPbeta led to a complete down-regulation of antiapoptotic B-cell lymphoma 2 (BCL2) expression. In chromatin immunoprecipitation assays, C/EBPbeta directly bound to the promoter region of IRF4, BLIMP1, and BCL2. Our data indicate that C/EBPbeta is involved in the regulatory network of transcription factors that are critical for plasma cell differentiation and survival. Targeting C/EBPbeta may provide a novel therapeutic strategy in the treatment of multiple myeloma.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19717648 PMCID: PMC2773489 DOI: 10.1182/blood-2009-01-201111
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113